MNT – Study shows NovoRapid® (insulin aspart) and Levemir® (insulin detemir) significantly reduce severe hypoglycaemia

Data from the independent investigator-initiated HypoAna study published in The Lancet Diabetes & Endocrinology, shows that Novo Nordisk’s short-acting and long-acting modern insulin analogues NovoRapid® (insulin aspart) and Levemir® (insulin detemir) significantly reduce severe hypoglycaemia in people with type 1 diabetes compared to human insulin (regular/NPH).

Read more

Posted in Type I Glucose & Insulin